Peptide News Digest

#Phase-3-H1-2027

3 stories

Industry · View digest

Silence Therapeutics (NASDAQ: SLN) Announced the Closing of Its Upsized $201.3 Million Underwritten Public Offering of American Depositary Shares Priced August 11 at $13.50 per ADS for 12,962,963 ADSs, With Underwriters (Jefferies, Morgan Stanley, Cantor Fitzgerald, and William Blair as Joint Book-Running Managers) Fully Exercising Their 30-Day Option to Purchase an Additional 1,944,444 ADSs Bringing Total to 14,907,407 ADSs; The Financing Follows the August 10 Phase 2 SANRECO Trial Win in Polycythemia Vera With Divesiran (First-in-Class TMPRSS6-Targeting siRNA) Achieving an 88% Response Rate Versus 19% on Placebo (P<0.0001, 69% Placebo-Adjusted Response Rate); Capital Advances Divesiran Into Phase 3 (Planned H1 2027) Plus Broader Hepatic-Target GalNAc-Conjugated siRNA Portfolio Progression

Silence Therapeutics (NASDAQ: SLN) announced the closing of its upsized $201.3 million underwritten public offering of American Depositary Shares. Terms: priced August 11 at $13.50 per ADS for 12,962,963 ADSs. The underwriters (Jefferies, Morgan Stanley, Cantor Fitzgerald, and William Blair as joint book-running managers) fully exercised their 30-day option to purchase an additional 1,944,444 ADSs, bringing the total offering to 14,907,407 ADSs and gross proceeds to approximately $201.3 million. The financing follows the August 10 Phase 2 SANRECO trial win in polycythemia vera with divesiran (first-in-class TMPRSS6-targeting siRNA that increases hepcidin production to restrict iron availability to bone marrow) achieving an 88% response rate versus 19% on placebo (P<0.0001, 69% placebo-adjusted response rate) in 48 phlebotomy-dependent patients over 36 weeks. Use of proceeds: advance divesiran into Phase 3 (planned initiation H1 2027 evaluating Q12W dosing versus placebo) plus broader pipeline progression including hepatic-target GalNAc-conjugated siRNA portfolio across TMPRSS6, complement component 3 (SLN-124/SLN-501), and other liver-targeted RNAi candidates. Divesiran has FDA Fast Track and Orphan Drug designations for polycythemia vera.

Clinical Trials · View digest

Kailera Therapeutics (NASDAQ: KLRA) Reported August 12 Q2 2026 Financial Results and Disclosed an Active Investigational New Drug (IND) Application With the US FDA for Ribupatide Oral (KAI-9531-T), a Triple Agonist (GLP-1/GIP/Glucagon) Peptide for Obesity Being Co-Developed With Hengrui Pharma, With Global Phase 3 Obesity Trials Planned to Initiate in H1 2027 Following Hengrui's Phase 2 Trial in Adults With Obesity That Documented Up to 12.1% Mean Weight Loss With No Observed Plateau at Week 26 and Up to 38.6% of Participants Achieving at Least 15% Weight Loss at the 25 mg and 50 mg Once-Daily Oral Doses; A Ribupatide Injection Phase 2b High-Dose Trial in Obesity Is Fully Enrolled With Data Anticipated in Mid-2027

Kailera Therapeutics (NASDAQ: KLRA) reported August 12, 2026 Q2 2026 financial results and disclosed an active Investigational New Drug (IND) application with the US FDA for ribupatide oral (KAI-9531-T), a triple agonist (GLP-1, GIP, and glucagon receptor) peptide for obesity being co-developed with Hengrui Pharma. Global Phase 3 obesity trials are planned to initiate in H1 2027. Phase 2 data foundation: Hengrui's Phase 2 trial in adults with obesity documented up to 12.1% mean weight loss with no observed plateau at Week 26 and up to 38.6% of participants achieving at least 15% weight loss at the 25 mg and 50 mg once-daily oral doses. A ribupatide injection Phase 2b high-dose trial in obesity is fully enrolled with data anticipated in mid-2027. Ribupatide competes mechanistically with Eli Lilly's retatrutide (once-weekly injectable triple agonist, roughly 28.7% weight loss at 68 weeks in Phase 3 TRIUMPH-4) in the triple-agonist class. The oral formulation could compete with Lilly's orforglipron (oral small-molecule GLP-1 agonist, roughly 7.5-11.2% weight loss over 72 weeks) and Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg). Kailera holds US and ex-China commercial rights via a license from Hengrui.

Clinical Trials · View digest

Silence Therapeutics (NASDAQ: SLN) Announced Positive Topline Results From the Phase 2 SANRECO Trial of Divesiran, a First-in-Class TMPRSS6-Targeting siRNA That Increases Hepcidin Production to Restrict Iron Availability to Bone Marrow and Reduce Excessive Red Blood Cell Production in Polycythemia Vera (PV); Trial Enrolled 48 Phlebotomy-Dependent PV Patients With Divesiran 6 mg/kg Administered Subcutaneously Every 6 Weeks or Every 12 Weeks; 88% of Divesiran-Treated Patients Achieved a Response Versus 19% on Placebo (P<0.0001), Corresponding to a 69% Placebo-Adjusted Response Rate; Divesiran Has FDA Fast Track and Orphan Drug Designations for PV; Company Anticipates Initiating a Phase 3 Trial Evaluating Divesiran Every 12 Weeks Versus Placebo in H1 2027 Extending the Broader siRNA Cardiometabolic and Rare-Disease Franchise Landscape That Also Includes Alnylam's Amvuttra and Arrowhead's Redemplo (Plozasiran)

Silence Therapeutics (NASDAQ: SLN) announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class TMPRSS6-targeting siRNA product candidate developed from the company's proprietary mRNAi GOLD platform. The trial enrolled 48 phlebotomy-dependent adults with polycythemia vera (PV) and evaluated divesiran 6 mg/kg administered subcutaneously every 6 weeks (Q6W) or every 12 weeks (Q12W) versus placebo over a 36-week randomized double-blind period. Results: 88% of divesiran-treated patients achieved a response versus 19% on placebo (P<0.0001), corresponding to a 69% placebo-adjusted response rate. How divesiran works: it silences TMPRSS6 (transmembrane serine protease 6) expressed almost exclusively in the liver; TMPRSS6 is a negative regulator of hepcidin, the body's master regulator of iron metabolism. By silencing TMPRSS6, divesiran increases hepcidin production and release by liver hepatocytes, which restricts iron availability to bone marrow and reduces the excessive red blood cell production that drives PV symptoms. Divesiran has FDA Fast Track and Orphan Drug designations for PV. Silence Therapeutics anticipates initiating a Phase 3 trial evaluating divesiran Q12W versus placebo in the first half of 2027. Shares rose sharply on the news, touching a 52-week high. The read-through extends the broader siRNA cardiometabolic and rare-disease franchise landscape that also includes Alnylam's Amvuttra and Arrowhead's Redemplo (plozasiran) in adjacent hepatic-target siRNA categories.